up-to-date with a click!
Update October, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications October 2018

Add on treatments

  1. Joseph P, Pais P, Dans AL et al. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. Am Heart J 2018; 206:72-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342297
  2. Pradhan AD, Paynter NP, Everett BM et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 2018; 206:80-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342298
  3. Kuhlman AB, Morville T, Dohlmann TL et al. Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women; the LIFESTAT study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30273493
  4. Park KY, Heo TH. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in LDLR KO mice. Cardiovasc Ther 2018:e12476. http://www.ncbi.nlm.nih.gov/pubmed/?term=30378752
  5. Donzelli A, Schivalocchi A, Giudicatti G. Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 138:1912-1913. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354663
  6. Koh KK. Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 138:1914-1915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354661
  7. Parra-Virto A, Torres do Rego A, Demelo-Rodriguez P et al. Usefulness of compounds with monacolin K in a case of statins intolerance. Clin Investig Arterioscler 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30309697
  8. Mottl AK, Buse JB, Ismail-Beigi F et al. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361335
  9. Lorenzi M, Ambegaonkar B, Baxter CA et al. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical research in cardiology : official journal of the German Cardiac Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302558
  10. Warraich HJ, Rana JS. Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. Current cardiology reports 2018; 20:125. http://www.ncbi.nlm.nih.gov/pubmed/?term=30311078
  11. Thompson PL, Nidorf SM. Colchicine: an affordable anti-inflammatory agent for atherosclerosis. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30320614
  12. Elsby R, Hare V, Neal H et al. Mechanistic in vitro studies indicate that the clinical drug-drug interaction between telithromycin and simvastatin acid is driven by time-dependent inhibition of CYP3A4 with minimal effect on OATP1B1. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348903
  13. Cifkova R. Antiplatelet and Lipid-lowering Drugs in Hypertension. European cardiology 2014; 9:16-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=30310480
  14. Balk EM, Adams GP, Langberg V et al. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Evidence report/technology assessment 2016:1-1252. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307737
  15. Nerild HH, Christensen MB, Knop FK, Bronden A. Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. Expert opinion on drug discovery 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336707
  16. Franczyk B, Gluba-Brzozka A, Jurkiewicz L et al. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Expert Opin Pharmacother 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30295098
  17. Nelson CP, Erridge C. Are toll-like receptors potential drug targets for atherosclerosis? Evidence from genetic studies to date. Immunogenetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30327825
  18. Barkate H, Patel P, Shah D, Vyas F. Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population. Indian journal of endocrinology and metabolism 2018; 22:627-631. http://www.ncbi.nlm.nih.gov/pubmed/?term=30294571
  19. Tuteja S, Qu L, Vujkovic M et al. Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. J Am Heart Assoc 2018; 7:e03488. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371334
  20. Vallejo-Vaz AJ, Ginsberg HN, Davidson MH et al. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc 2018; 7:e009221. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371190
  21. Sawami K, Tanaka A, Nakamura T et al. Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia. Journal of cardiology cases 2018; 17:204-207. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279893
  22. Mirzaee S, Thein PM, Nogic J et al. The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. J Clin Lipidol 2018; 12:1133-1140.e1115. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318063
  23. Sarsam S, Berry A, Degheim G et al. Real-world use of PCSK9 inhibitors: A single-center experience. J Int Med Res 2018:300060518800595. http://www.ncbi.nlm.nih.gov/pubmed/?term=30280628
  24. Wang L, Wang Y, Yu L et al. Direct Differentiation of Stereoisomers of Ezetimibe/Ambrisentan/Atorvastatin and their Mechanism Study by Electrospray Ionization Quadurupole Time-of-Flight Mass Spectrometry. Journal of mass spectrometry : JMS 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276925
  25. Slomski A. Benefits May Persist After Antihypertensive and Statin Treatment. Jama 2018; 320:1631. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357296
  26. Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis 2018; 17:239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30326894
  27. Sharma A, Mohan N. Role of niacin in current clinical practice: a review. Minerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334440
  28. Woo Y, Shin JS, Shim CY et al. Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction. PLoS One 2018; 13:e0205006. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286170
  29. Han JS, Kim K, Jung Y et al. Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin. Scientific reports 2018; 8:14642. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279504

Adherence

  1. Bergstrom H, Branvall E, Helde-Frankling M, Bjorkhem-Bergman L. Differences in discontinuation of statin treatment in women and men with advanced cancer disease. Biology of sex differences 2018; 9:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342545
  2. Rea F, Calusi G, Franchi M et al. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation. Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361806
  3. Chung PW, Yoon BW, Lee YB et al. Medication Adherence of Statin Users after Acute Ischemic Stroke. European neurology 2018; 80:106-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30347393
  4. Boulmpou A, Kartas A, Farmakis I et al. Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy compliance in patients with Acute Coronary Syndromes (IDEAL-LDL) Study: Rationale and design. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30352291
  5. Vallejo-Vaz AJ, Ginsberg HN, Davidson MH et al. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc 2018; 7:e009221. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371190
  6. Banegas MP, Emerson MA, Adams AS et al. Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer. Journal of cancer survivorship : research and practice 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30338462
  7. J BS, Holleman RG, Youles B, Lowery JC. Quality Improvement and Personalization for Statins: the QUIPS Quality Improvement Randomized Trial of Veterans' Primary Care Statin Use. Journal of general internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30284172
  8. Kumamaru H, Lee MP, Choudhry NK et al. Using Previous Medication Adherence to Predict Future Adherence. Journal of managed care & specialty pharmacy 2018; 24:1146-1155. http://www.ncbi.nlm.nih.gov/pubmed/?term=30362915

Atherosclerosis & Imaging

  1. Di Bartolo BA, Psaltis PJ, Bursill CA, Nicholls SJ. Translating Evidence of HDL and Plaque Regression. Arterioscler Thromb Vasc Biol 2018; 38:1961-1968. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354261
  2. Sakamoto A, Virmani R, Finn AV. Coronary artery calcification: recent developments in our understanding of its pathologic and clinical significance. Current opinion in cardiology 2018; 33:645-652. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307412
  3. Grigoropoulou P, Tentolouris A, Eleftheriadou I et al. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research 2018:1479164118805320. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328360
  4. de Knegt MC, Linde JJ, Fuchs A et al. Relationship between patient presentation and morphology of coronary atherosclerosis by quantitative multidetector computed tomography. European heart journal cardiovascular Imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30325406
  5. Wang XL, Sun W, Zhou YL, Li L. Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Halpha1 in ApoE(-/-) mice. The international journal of biochemistry & cell biology 2018; 105:70-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336263
  6. Nicholls SJ, Puri R, Anderson T et al. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol 2018; 72:2012-2021. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336824
  7. Barshes NR. Nascent Medical Therapies for Abdominal Aneurysms. J Am Heart Assoc 2018; 7:e010458. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371312
  8. Hussain MA, Saposnik G, Raju S et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc 2018; 7:e009745. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369318
  9. Wander GS, Hukkeri MYK, Yalagudri S et al. Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease. The Journal of the Association of Physicians of India 2018; 66:65-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=30341873
  10. Deseive S, Straub R, Kupke M et al. Impact of diabetes on coronary artery plaque volume by coronary CT angiography and subsequent adverse cardiac events. Journal of cardiovascular computed tomography 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30293793
  11. Firouzi A, Kazem Moussavi A, Mohebbi A et al. Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention. Journal of cardiovascular and thoracic research 2018; 10:149-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=30386535
  12. Mirzaee S, Thein PM, Nogic J et al. The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. J Clin Lipidol 2018; 12:1133-1140.e1115. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318063
  13. Nicholls SJ, Nelson AJ. Monitoring the Response to Statin Therapy: One Scan at a Time. JACC. Cardiovascular imaging 2018; 11:1485-1486. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286908

Atorvastatin/Rosuvastatin

  1. Rosas Saldarriaga D, Berrouet Mejia MC. Atorvastatin-Associated DRESS Syndrome. American journal of therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30272596
  2. Dourado PMM. Rosuvastatin Decreases the Formation of Neointima by Increasing Apo J, Reducing Restenosis after Balloon Injury in Rats. Arquivos brasileiros de cardiologia 2018; 111:569-570. http://www.ncbi.nlm.nih.gov/pubmed/?term=30365679
  3. Yang N, Dong B, Yang J et al. Effects of Rosuvastatin on Apolipoprotein J in Balloon-Injured Carotid Artery in Rats. Arquivos brasileiros de cardiologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30281685
  4. Nayak A, Hayen A, Zhu L et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open 2018; 8:e020584. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287603
  5. Abdollahimajd F, Rajabi F, Shahidi-Dadras M et al. Pachyonychia congenita: A case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307612
  6. Ren C, Li S, Liu K et al. Enhanced oxidative stress response and neuroprotection of combined limb remote ischemic conditioning and atorvastatin after transient ischemic stroke in rats. Brain circulation 2017; 3:204-212. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276326
  7. Marchetti DP, Steffens L, Jacques CE et al. Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-L-cysteine, Trolox, and Rosuvastatin. Cellular and molecular neurobiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302628
  8. Peto R, Collins R. Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects. Circulation 2018; 138:1499-1501. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354509
  9. Husain I, Khan S, Khan S et al. Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders. Clin Exp Pharmacol Physiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30290001
  10. Cavallari I, Delli Veneri A, Maddaloni E et al. Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current diabetes reports 2018; 18:138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30370486
  11. Spiridon AM, Neamtu J, Belu I et al. Simultaneous Analysis of Clopidogrel Bisulfate, Acetylsalicylic Acid and Atorvastatin calcium in Tablets by HPLC Method. Current health sciences journal 2015; 41:172-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364896
  12. Krysiak R, Szkrobka W, Okopien B. Atorvastatin potentiates the effect of selenomethionine on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis. Current medical research and opinion 2018:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354702
  13. Grigoropoulou P, Tentolouris A, Eleftheriadou I et al. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research 2018:1479164118805320. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328360
  14. Itoh H, Ueshima K, Komuro I. Response to Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275-1284. Diabetes Care 2018; 41:e145-e146. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348847
  15. Moore N, Duret S, Grolleau A et al. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361989
  16. Ghasemi A, Ghashghai Z, Akbari J et al. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30291370
  17. Chung PW, Yoon BW, Lee YB et al. Medication Adherence of Statin Users after Acute Ischemic Stroke. European neurology 2018; 80:106-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30347393
  18. Magdy YM, El-Kharashi OA, El-Waseef DAA et al. Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy. Experimental and molecular pathology 2018; 105:293-310. http://www.ncbi.nlm.nih.gov/pubmed/?term=30308196
  19. Liu J, Huang H, Shi S et al. Atorvastatin upregulates apolipoprotein M expression via attenuating LXRalpha expression in hyperlipidemic apoE-deficient mice. Experimental and therapeutic medicine 2018; 16:3785-3792. http://www.ncbi.nlm.nih.gov/pubmed/?term=30344653
  20. Teschke R. Top ranking drugs out of 3312 drug induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. Expert Opin Drug Metab Toxicol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354694
  21. Barkate H, Patel P, Shah D, Vyas F. Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population. Indian journal of endocrinology and metabolism 2018; 22:627-631. http://www.ncbi.nlm.nih.gov/pubmed/?term=30294571
  22. Wang XL, Sun W, Zhou YL, Li L. Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Halpha1 in ApoE(-/-) mice. The international journal of biochemistry & cell biology 2018; 105:70-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336263
  23. Lin PY, Lee FY, Wallace CG et al. Corrigendum to "The therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced rabbit aortic atherosclerosis and stiffness" [Int. J. Cardiol. 227 (2017) 938-949]. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30384978
  24. Zhang H, Lu X, Liu Z, Du K. Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. International journal of molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30320373
  25. Sinha P, Delucchi KL, Thompson BT et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive care medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30291376
  26. Kim J, Park KT, Jang MJ et al. High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention. J Am Heart Assoc 2018; 7:e009517. http://www.ncbi.nlm.nih.gov/pubmed/?term=30376751
  27. Wander GS, Hukkeri MYK, Yalagudri S et al. Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease. The Journal of the Association of Physicians of India 2018; 66:65-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=30341873
  28. Firouzi A, Kazem Moussavi A, Mohebbi A et al. Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention. Journal of cardiovascular and thoracic research 2018; 10:149-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=30386535
  29. Cheng Y, Sun T, Yin C et al. Downregulation of PTEN by sodium orthovanadate protects the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30368869
  30. Carrillo-Ibarra S, Miranda-Diaz AG, Sifuentes-Franco S et al. Effect of statins on oxidative DNA damage in diabetic polyneuropathy. Journal of circulating biomarkers 2018; 7:1849454418804099. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302131
  31. Zapata-Catzin GA, Bonilla-Hernandez M, Vargas-Coronado RF et al. Effect of the rigid segment content on the properties of segmented polyurethanes conjugated with atorvastatin as chain extender. Journal of materials science. Materials in medicine 2018; 29:161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357534
  32. Barnett S, Ogungbenro K, Menochet K et al. Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared to rosuvastatin and coproporphyrin I. J Pharmacol Exp Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30314992
  33. Nicholls SJ, Nelson AJ. Monitoring the Response to Statin Therapy: One Scan at a Time. JACC. Cardiovascular imaging 2018; 11:1485-1486. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286908
  34. Slomski A. Benefits May Persist After Antihypertensive and Statin Treatment. Jama 2018; 320:1631. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357296
  35. Du J, Zhu Y, Meng X et al. Atorvastatin attenuates paraquat poisoning-induced epithelial-mesenchymal transition via downregulating hypoxia-inducible factor-1 alpha. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336147
  36. El Sayed I, Helmy MW, El-Abhar HS. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30292831
  37. Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis 2018; 17:239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30326894
  38. Liu H, Dong A, Wang H. Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study. Medicine (Baltimore) 2018; 97:e12687. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334951
  39. Yang Q, Yin RX, Cao XL et al. ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses. Nutrition & metabolism 2018; 15:70. http://www.ncbi.nlm.nih.gov/pubmed/?term=30323852
  40. Rahim F, Sayyah M. Effects of atorvastatin on treatment-resistant obsessive-compulsive disorder: A double-blind randomized trial. Psychiatria polska 2018; 52:719-729. http://www.ncbi.nlm.nih.gov/pubmed/?term=30368541
  41. Lee OS, Zhang J, Jung SH et al. High-Intensity Statin Therapy Is "Too Much," Thus Not Indicated for Very Elderly Patients. Pulse (Basel, Switzerland) 2018; 6:19-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30283750
  42. Han JS, Kim K, Jung Y et al. Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin. Scientific reports 2018; 8:14642. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279504
  43. Nunez-Garcia M, Gomez-Santos B, Saenz de Urturi D et al. Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice. Scientific reports 2018; 8:14626. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279550
  44. Hu MB, Zhang JW, Gao JB et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastructural pathology 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30300062

Basic science

  1. Fahmy UA. Augmentation of Fluvastatin Cytotoxicity Against Prostate Carcinoma PC3 Cell Line Utilizing Alpha Lipoic-Ellagic Acid Nanostructured Lipid Carrier Formula. AAPS PharmSciTech 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30350252
  2. Yang N, Dong B, Yang J et al. Effects of Rosuvastatin on Apolipoprotein J in Balloon-Injured Carotid Artery in Rats. Arquivos brasileiros de cardiologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30281685
  3. Sedki M, Khalil IA, El-Sherbiny IM. Hybrid nanocarrier system for guiding and augmenting simvastatin cytotoxic activity against prostate cancer. Artificial cells, nanomedicine, and biotechnology 2018:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30295086
  4. Chimini JS, Possomato-Vieira JS, Silva M, Dias-Junior CA. Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318719
  5. Yan S, Ren J, Jian Y et al. Injectable maltodextrin based micelle/ hydrogel composites for simvastatin controlled release. Biomacromolecules 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30350597
  6. Al-Hashimi NN, Shahin RO, Al-Hashimi AN et al. Cetyl-alcohol-reinforced hollow fiber solid/liquid phase microextraction and HPLC-DAD analysis of ezetimibe and simvastatin in human plasma and urine. Biomedical chromatography : BMC 2018:e4410. http://www.ncbi.nlm.nih.gov/pubmed/?term=30315647
  7. Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance-The antagonistic drug-drug interactions versus the anti-cancer effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 108:1856-1865. http://www.ncbi.nlm.nih.gov/pubmed/?term=30372891
  8. Chen Y, Zhu R, Ma F et al. Assessment of OATP Transporter-Mediated Drug-Drug Interaction using Physiologically-Based Pharmacokinetic (PBPK) Modeling - A Case Example. Biopharmaceutics & drug disposition 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30335192
  9. Yu P, Yang X, Qi Z. Letter to the editor: The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats. Bone 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30366110
  10. Ren C, Li S, Liu K et al. Enhanced oxidative stress response and neuroprotection of combined limb remote ischemic conditioning and atorvastatin after transient ischemic stroke in rats. Brain circulation 2017; 3:204-212. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276326
  11. Park KY, Heo TH. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in LDLR KO mice. Cardiovasc Ther 2018:e12476. http://www.ncbi.nlm.nih.gov/pubmed/?term=30378752
  12. Xia Y, Xie Y, Yu Z et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270039
  13. Marchetti DP, Steffens L, Jacques CE et al. Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-L-cysteine, Trolox, and Rosuvastatin. Cellular and molecular neurobiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302628
  14. Liu Z, Lai CH, Zhang X et al. Simvastatin ameliorates total liver ischemia/reperfusion injury via KLF2-mediated mechanism in rats. Clin Res Hepatol Gastroenterol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30274910
  15. Spiridon AM, Neamtu J, Belu I et al. Simultaneous Analysis of Clopidogrel Bisulfate, Acetylsalicylic Acid and Atorvastatin calcium in Tablets by HPLC Method. Current health sciences journal 2015; 41:172-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364896
  16. Korani S, Korani M, Bahrami S et al. Application of nanotechnology to improve the therapeutic benefits of statins. Drug discovery today 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30292917
  17. Braga Filho JAF, Abreu AG, Rios CEP et al. Prophylactic Treatment With Simvastatin Modulates the Immune Response and Increases Animal Survival Following Lethal Sepsis Infection. Frontiers in immunology 2018; 9:2137. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298072
  18. Tryggvadottir H, Huzell L, Gustbee E et al. Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients. Frontiers in oncology 2018; 8:428. http://www.ncbi.nlm.nih.gov/pubmed/?term=30370250
  19. Wang XL, Sun W, Zhou YL, Li L. Rosuvastatin stabilizes atherosclerotic plaques by reducing CD40L overexpression-induced downregulation of P4Halpha1 in ApoE(-/-) mice. The international journal of biochemistry & cell biology 2018; 105:70-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336263
  20. Lin PY, Lee FY, Wallace CG et al. Corrigendum to "The therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced rabbit aortic atherosclerosis and stiffness" [Int. J. Cardiol. 227 (2017) 938-949]. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30384978
  21. Zhang H, Lu X, Liu Z, Du K. Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. International journal of molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30320373
  22. Deng LJ, Wu YL, He XH et al. Simvastatin delivery on PEEK for bioactivity and osteogenesis enhancements. Journal of biomaterials science. Polymer edition 2018:1-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307376
  23. Zdybel M, Chodurek E, Pilawa B. Effect of simvastatin in different concentrations on free radicals in A-2058 human melanoma malignum cells-EPR studies. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30277600
  24. Pei WN, Hu HJ, Liu F et al. C-reactive protein aggravates myocardial ischemia/reperfusion injury through activation of extracellular-signal-regulated kinase 1/2. Journal of geriatric cardiology : JGC 2018; 15:492-503. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364730
  25. Wang L, Wang Y, Yu L et al. Direct Differentiation of Stereoisomers of Ezetimibe/Ambrisentan/Atorvastatin and their Mechanism Study by Electrospray Ionization Quadurupole Time-of-Flight Mass Spectrometry. Journal of mass spectrometry : JMS 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276925
  26. Zapata-Catzin GA, Bonilla-Hernandez M, Vargas-Coronado RF et al. Effect of the rigid segment content on the properties of segmented polyurethanes conjugated with atorvastatin as chain extender. Journal of materials science. Materials in medicine 2018; 29:161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357534
  27. Zhou TY, Zhou YL, Qian MJ et al. Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages. Journal of pharmacological sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30340922
  28. Han KH. Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism. Korean Circ J 2018; 48:951-963. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334382
  29. Du J, Zhu Y, Meng X et al. Atorvastatin attenuates paraquat poisoning-induced epithelial-mesenchymal transition via downregulating hypoxia-inducible factor-1 alpha. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336147
  30. El Sayed I, Helmy MW, El-Abhar HS. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30292831
  31. Verma M, Nanda A, Kumar Y. Self-Emulsifying Drug Delivery System of Simvastatin: Formulation Development, Optimization by Box- Behnken Design, In-Vitro and In-Situ Single-Pass Intestinal Perfusion (SPIP) Studies. Recent patents on drug delivery & formulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30345934
  32. Medeiros ADC, Azevedo IM, Lima ML et al. Effects of simvastatin on 5-fluorouracil-induced gastrointestinal mucositis in rats. Revista do Colegio Brasileiro de Cirurgioes 2018; 45:e1968. http://www.ncbi.nlm.nih.gov/pubmed/?term=30379218
  33. Nezic L, Skrbic R, Amidzic L et al. Simvastatin Protects Cardiomyocytes Against Endotoxin-induced Apoptosis and Up-regulates Survivin/NF-kappaB/p65 Expression. Scientific reports 2018; 8:14652. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279549
  34. Nunez-Garcia M, Gomez-Santos B, Saenz de Urturi D et al. Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice. Scientific reports 2018; 8:14626. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279550
  35. Ruiz-DeDiego I, Fasano S, Solis O et al. Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin. Scientific reports 2018; 8:15381. http://www.ncbi.nlm.nih.gov/pubmed/?term=30337665
  36. Irwin JC, Fenning AS, Ryan KR, Vella RK. Validation of a clinically-relevant rodent model of statin-associated muscle symptoms for use in pharmacological studies. Toxicology and applied pharmacology 2018; 360:78-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=30268577
  37. Hu MB, Zhang JW, Gao JB et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastructural pathology 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30300062

Cancer

  1. Fahmy UA. Augmentation of Fluvastatin Cytotoxicity Against Prostate Carcinoma PC3 Cell Line Utilizing Alpha Lipoic-Ellagic Acid Nanostructured Lipid Carrier Formula. AAPS PharmSciTech 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30350252
  2. Sedki M, Khalil IA, El-Sherbiny IM. Hybrid nanocarrier system for guiding and augmenting simvastatin cytotoxic activity against prostate cancer. Artificial cells, nanomedicine, and biotechnology 2018:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30295086
  3. Bergstrom H, Branvall E, Helde-Frankling M, Bjorkhem-Bergman L. Differences in discontinuation of statin treatment in women and men with advanced cancer disease. Biology of sex differences 2018; 9:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342545
  4. Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance-The antagonistic drug-drug interactions versus the anti-cancer effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 108:1856-1865. http://www.ncbi.nlm.nih.gov/pubmed/?term=30372891
  5. Chidwick K, Strongman H, Matthews A et al. Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink. BMC Cancer 2018; 18:1018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348123
  6. Langballe R, Cronin-Fenton D, Dehlendorff C et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. Br J Cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30353047
  7. Chen WC, Boursi B, Mamtani R, Yang YX. Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30333217
  8. Mondul AM, Joshu CE, Barber JR et al. Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study. Cancer prevention research (Philadelphia, Pa.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30327368
  9. Xia Y, Xie Y, Yu Z et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270039
  10. Aminsharifi A, Howard LE, Amling CL et al. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clinical genitourinary cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30366879
  11. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30314951
  12. Ghasemi A, Ghashghai Z, Akbari J et al. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30291370
  13. Alawami M, Wimalasena S, Ghashi R, Alnasrallah B. Acute Arterial Cardiovascular Events Risk in Patients with Primary Membranous Nephropathy. Internal medicine journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30346109
  14. Banegas MP, Emerson MA, Adams AS et al. Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer. Journal of cancer survivorship : research and practice 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30338462
  15. Jang HJ, Kim HS, Kim JH, Lee J. The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials. Journal of clinical medicine 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287761
  16. Zhou TY, Zhou YL, Qian MJ et al. Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages. Journal of pharmacological sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30340922
  17. Ederhy S, Ancedy Y, Soulat-Dufour L et al. [Is cancer a factor or a marker of cardiovascular risk in women?]. Presse medicale (Paris, France : 1983) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30293849
  18. Hu MB, Zhang JW, Gao JB et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastructural pathology 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30300062

Children

  1. Radaelli G, Sausen G, Cesa CC et al. Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis. Arquivos brasileiros de cardiologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30365601
  2. Iughetti L, Predieri B, Bruzzi P, Balli F. Approaches to dyslipidemia treatment in children and adolescents. Expert review of endocrinology & metabolism 2008; 3:615-633. http://www.ncbi.nlm.nih.gov/pubmed/?term=30290407
  3. Desai NK, Mendelson MM, Baker A et al. Hepatotoxicity of Statins as determined by Serum Alanine Aminotransferase in a Pediatric Cohort with Dyslipidemia. Journal of pediatric gastroenterology and nutrition 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334928

Cost-effectiveness

  1. Toth PP, Granowitz C, Hull M et al. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. J Am Heart Assoc 2018; 7:e008740. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371242

CVD

  1. Lee CH, Fang CC, Tsai LM et al. Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30301543
  2. Ge Z, Baber U, Claessen BE et al. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30351514
  3. Bodde MC, Hermans MPJ, Jukema JW et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical research in cardiology : official journal of the German Cardiac Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298424
  4. Petrov IS, Postadzhiyan AS, Tokmakova MP et al. Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia medica 2018; 60:389-396. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355848
  5. Alawami M, Wimalasena S, Ghashi R, Alnasrallah B. Acute Arterial Cardiovascular Events Risk in Patients with Primary Membranous Nephropathy. Internal medicine journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30346109
  6. Barshes NR. Nascent Medical Therapies for Abdominal Aneurysms. J Am Heart Assoc 2018; 7:e010458. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371312
  7. Hussain MA, Saposnik G, Raju S et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc 2018; 7:e009745. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369318
  8. Kim J, Park KT, Jang MJ et al. High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention. J Am Heart Assoc 2018; 7:e009517. http://www.ncbi.nlm.nih.gov/pubmed/?term=30376751
  9. Salata K, Syed M, Hussain MA et al. Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2018; 7:e008657. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371297
  10. Schousboe JT, Kats AM, Langsetmo L et al. Central Obesity and Visceral Adipose Tissue Are Not Associated With Incident Atherosclerotic Cardiovascular Disease Events in Older Men. J Am Heart Assoc 2018; 7:e009172. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369326
  11. Toth PP, Granowitz C, Hull M et al. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. J Am Heart Assoc 2018; 7:e008740. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371242
  12. Wander GS, Hukkeri MYK, Yalagudri S et al. Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease. The Journal of the Association of Physicians of India 2018; 66:65-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=30341873
  13. Sorber R, Lehman A, Alshaikh HN et al. Metabolic syndrome is associated with increased cardiac morbidity after infrainguinal bypass surgery irrespective of the use of cardiovascular risk-modifying agents. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30292611
  14. Guntekin U, Tosun V, Kilinc AY et al. ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals: A retrospective analysis of patients presenting with first acute coronary syndromes. Medicine (Baltimore) 2018; 97:e12225. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278492
  15. Kuang H, Zhou X, Li L et al. Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report. Medicine (Baltimore) 2018; 97:e12869. http://www.ncbi.nlm.nih.gov/pubmed/?term=30335000
  16. Liu H, Dong A, Wang H. Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study. Medicine (Baltimore) 2018; 97:e12687. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334951

Endothelium/inflammation

  1. Cainzos-Achirica M, Enjuanes C, Greenland P et al. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2018; 278:217-225. http://www.ncbi.nlm.nih.gov/pubmed/?term=30312930
  2. Thompson PL, Nidorf SM. Colchicine: an affordable anti-inflammatory agent for atherosclerosis. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30320614
  3. Lorenzatti A, Servato ML. Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). European cardiology 2018; 13:38-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30310469
  4. Zhang H, Lu X, Liu Z, Du K. Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. International journal of molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30320373
  5. Kitagawa K, Hosomi N, Nagai Y et al. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318492
  6. Pei WN, Hu HJ, Liu F et al. C-reactive protein aggravates myocardial ischemia/reperfusion injury through activation of extracellular-signal-regulated kinase 1/2. Journal of geriatric cardiology : JGC 2018; 15:492-503. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364730
  7. Nimitphong H, Mahattanapreut A, Chailurkit LO et al. More evening preference is positively associated with systemic inflammation in prediabetes and type 2 diabetes patients. Scientific reports 2018; 8:15882. http://www.ncbi.nlm.nih.gov/pubmed/?term=30367094

Ethnicity

  1. Li YH, Chao TH, Liu PY et al. Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiologica Sinica 2018; 34:371-378. http://www.ncbi.nlm.nih.gov/pubmed/?term=30271086
  2. Lee CH, Fang CC, Tsai LM et al. Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30301543
  3. Harada PH, Miname MH, Bensenor IM et al. Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil. Atherosclerosis 2018; 277:273-277. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270058
  4. Kayikcioglu M, Tokgozoglu L, Dogan V et al. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? Atherosclerosis 2018; 277:341-346. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270069
  5. Lalic K, Rajkovic N, Popovic L et al. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia. Atherosclerosis 2018; 277:298-303. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270062
  6. Latkovskis G, Saripo V, Gilis D et al. Latvian registry of familial hypercholesterolemia: The first report of three-year results. Atherosclerosis 2018; 277:347-354. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270070
  7. Shek A, Alieva R, Kurbanov R et al. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle. Atherosclerosis 2018; 277:524-529. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270094
  8. Truong TH, Kim NT, Nguyen MNT et al. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis 2018; 277:392-398. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270076
  9. van Delden XM, Huijgen R, Wolmarans KH et al. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. Atherosclerosis 2018; 277:327-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270067
  10. Petrov IS, Postadzhiyan AS, Tokmakova MP et al. Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia medica 2018; 60:389-396. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355848
  11. Kajinami K, Ozaki A, Tajima Y et al. Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369517
  12. Srivanichakorn W, Godsland IF, Washirasaksiri C et al. Cardiometabolic risk factors in Thai individuals with prediabetes treated in a high-risk, prevention clinic - unexpected relationship between HDL cholesterol and glycaemia in men. Journal of diabetes investigation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30387292
  13. Goh CC, Koh KH, Goh S et al. Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2018; 13:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302178
  14. Basu S, Sussman JB, Hayward RA. Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit-Based Lipid and Blood Pressure Treatment. MDM policy & practice 2017; 2:2381468317725741. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288429
  15. Liu H, Dong A, Wang H. Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study. Medicine (Baltimore) 2018; 97:e12687. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334951
  16. Lee OS, Zhang J, Jung SH et al. High-Intensity Statin Therapy Is "Too Much," Thus Not Indicated for Very Elderly Patients. Pulse (Basel, Switzerland) 2018; 6:19-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30283750
  17. Yan MM, Wu SS, Ying YQ et al. Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE open medicine 2018; 6:2050312118798278. http://www.ncbi.nlm.nih.gov/pubmed/?term=30345053

FH

  1. Chemaly P, Nallet O, Delarche N et al. [Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit]. Annales de cardiologie et d'angeiologie 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30290906
  2. Radaelli G, Sausen G, Cesa CC et al. Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis. Arquivos brasileiros de cardiologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30365601
  3. Beliard S, Boccara F, Cariou B et al. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Atherosclerosis 2018; 277:334-340. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270068
  4. Botha TC, Pilcher GJ, Wolmarans K et al. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis 2018; 277:502-507. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270091
  5. Dumitrescu A, Mosteoru S, Vinereanu D et al. Preliminary data of familial hypercholesterolemia (FH) patients in Romania. Atherosclerosis 2018; 277:304-307. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270063
  6. Harada PH, Miname MH, Bensenor IM et al. Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil. Atherosclerosis 2018; 277:273-277. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270058
  7. Kayikcioglu M, Tokgozoglu L, Dogan V et al. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? Atherosclerosis 2018; 277:341-346. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270069
  8. Lalic K, Rajkovic N, Popovic L et al. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia. Atherosclerosis 2018; 277:298-303. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270062
  9. Latkovskis G, Saripo V, Gilis D et al. Latvian registry of familial hypercholesterolemia: The first report of three-year results. Atherosclerosis 2018; 277:347-354. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270070
  10. Shek A, Alieva R, Kurbanov R et al. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle. Atherosclerosis 2018; 277:524-529. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270094
  11. Truong TH, Kim NT, Nguyen MNT et al. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis 2018; 277:392-398. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270076
  12. van Delden XM, Huijgen R, Wolmarans KH et al. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. Atherosclerosis 2018; 277:327-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270067
  13. Vohnout B, Fabryova L, Klabnik A et al. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. Atherosclerosis 2018; 277:323-326. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270066
  14. Vrablik M, Raslova K, Vohnout B et al. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis 2018; 277:355-361. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270071
  15. Schol-Gelok S, Galema-Boers J, van Gelder T et al. No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 108:1412-1414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30372843
  16. Iacocca MA, Wang J, Sarkar S et al. Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Can J Cardiol 2018; 34:1316-1324. http://www.ncbi.nlm.nih.gov/pubmed/?term=30269829
  17. Lambert CT, Sandesara P, Isiadinso I et al. Current Treatment of Familial Hypercholesterolaemia. European cardiology 2014; 9:76-81. http://www.ncbi.nlm.nih.gov/pubmed/?term=30310490
  18. Petrov IS, Postadzhiyan AS, Tokmakova MP et al. Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia medica 2018; 60:389-396. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355848
  19. Alver M, Palover M, Saar A et al. Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genetics in medicine : official journal of the American College of Medical Genetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270359
  20. Gaudet D, Langslet G, Gidding SS et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol 2018; 12:1199-1207. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318065
  21. Kuang H, Zhou X, Li L et al. Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report. Medicine (Baltimore) 2018; 97:e12869. http://www.ncbi.nlm.nih.gov/pubmed/?term=30335000

Genetics

  1. Iacocca MA, Wang J, Sarkar S et al. Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Can J Cardiol 2018; 34:1316-1324. http://www.ncbi.nlm.nih.gov/pubmed/?term=30269829
  2. Peyser B, Perry EP, Singh K et al. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circulation. Genomic and precision medicine 2018; 11:e002228. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354330
  3. Tuteja S, Rader DJ. SLCO1B1 and Statin Therapy. Circulation. Genomic and precision medicine 2018; 11:e002320. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354338
  4. Wu X, Gong C, Weinstock J et al. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018:1076029618805863. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336686
  5. Vassy JL, Brunette CA, Majahalme N et al. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemporary clinical trials 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30367991
  6. Athyros VG, Katsiki N, Dimakopoulou A et al. Drugs that mimic the effect of gene mutations for the prevention or the treatment of atherosclerotic disease: from PCSK9 inhibition to ANGPTL3 inactivation. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30306859
  7. Liu J, Huang H, Shi S et al. Atorvastatin upregulates apolipoprotein M expression via attenuating LXRalpha expression in hyperlipidemic apoE-deficient mice. Experimental and therapeutic medicine 2018; 16:3785-3792. http://www.ncbi.nlm.nih.gov/pubmed/?term=30344653
  8. Tryggvadottir H, Huzell L, Gustbee E et al. Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients. Frontiers in oncology 2018; 8:428. http://www.ncbi.nlm.nih.gov/pubmed/?term=30370250
  9. Alver M, Palover M, Saar A et al. Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. Genetics in medicine : official journal of the American College of Medical Genetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270359
  10. Tuteja S, Qu L, Vujkovic M et al. Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. J Am Heart Assoc 2018; 7:e03488. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371334
  11. Yang Q, Yin RX, Cao XL et al. ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses. Nutrition & metabolism 2018; 15:70. http://www.ncbi.nlm.nih.gov/pubmed/?term=30323852
  12. Xiang Q, Zhang X, Ma L et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenetics and genomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30363031
  13. Isackson PJ, Wang J, Zia M et al. RYR1 and CACNA1S genetic variants identified withf statin-associated muscle symptoms. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30325262
  14. Ruiz-Iruela C, Padro-Miquel A, Pinto-Sala X et al. KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment. PLoS One 2018; 13:e0205430. http://www.ncbi.nlm.nih.gov/pubmed/?term=30304062
  15. Uchiyama H, Tsujimoto M, Kimura A et al. Effects of Uremic Serum Residue on OATP1B1- and OATP1B3-Mediated Pravastatin Uptake in OATP-Expressing HEK293 Cells and Human Hepatocytes. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318712

Guidelines

  1. Li YH, Chao TH, Liu PY et al. Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiologica Sinica 2018; 34:371-378. http://www.ncbi.nlm.nih.gov/pubmed/?term=30271086
  2. Hermans MP, Gevaert S, Descamps O et al. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II CHD). Acta clinica Belgica 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355016
  3. Khariton Y, Patel KK, Chan PS et al. Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30284297
  4. Goh CC, Koh KH, Goh S et al. Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2018; 13:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302178
  5. Ye S, Leppin AL, Chan AY et al. An Informatics Approach to Implement Support for Shared Decision Making for Primary Prevention Statin Therapy. MDM policy & practice 2018; 3:2381468318777752. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288449
  6. Guntekin U, Tosun V, Kilinc AY et al. ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals: A retrospective analysis of patients presenting with first acute coronary syndromes. Medicine (Baltimore) 2018; 97:e12225. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278492
  7. Farnier M. [New guidelines on dyslipidemia management]. Presse medicale (Paris, France : 1983) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30274915

LDL- related parameters

  1. Hermans MP, Gevaert S, Descamps O et al. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II CHD). Acta clinica Belgica 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355016
  2. Lalic K, Rajkovic N, Popovic L et al. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia. Atherosclerosis 2018; 277:298-303. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270062
  3. Schmidt N, Dressel A, Grammer TB et al. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis 2018; 277:314-322. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270065
  4. Vohnout B, Fabryova L, Klabnik A et al. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice. Atherosclerosis 2018; 277:323-326. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270066
  5. Vrablik M, Raslova K, Vohnout B et al. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis 2018; 277:355-361. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270071
  6. Oni-Orisan A, Hoffmann TJ, Ranatunga D et al. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circulation. Genomic and precision medicine 2018; 11:e002043. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354326
  7. Bodde MC, Hermans MPJ, Jukema JW et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical research in cardiology : official journal of the German Cardiac Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298424
  8. Donzelli A, Schivalocchi A, Giudicatti G, Battaggia A. Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275-1284. Diabetes Care 2018; 41:e143-e144. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348846
  9. Ferrieres J, De Ferrari GM, Hermans MP et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol 2018:2047487318806359. http://www.ncbi.nlm.nih.gov/pubmed/?term=30335504
  10. Boulmpou A, Kartas A, Farmakis I et al. Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy compliance in patients with Acute Coronary Syndromes (IDEAL-LDL) Study: Rationale and design. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30352291
  11. Lowenstern AM, Li S, Navar AM et al. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. J Am Heart Assoc 2018; 7:e009251. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371214
  12. Kajinami K, Ozaki A, Tajima Y et al. Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369517
  13. Willeit P, Ridker PM, Nestel PJ et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30293769
  14. Goh CC, Koh KH, Goh S et al. Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2018; 13:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302178
  15. Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30375494
  16. Ruiz-Iruela C, Padro-Miquel A, Pinto-Sala X et al. KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment. PLoS One 2018; 13:e0205430. http://www.ncbi.nlm.nih.gov/pubmed/?term=30304062

Lifestyle

  1. Unlu S, Nurkoc SG, Sezenoz B et al. Impact of statin use on high sensitive troponin T levels with moderate exercise. Acta Cardiol 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328783
  2. Derosa G, Maffioli P. Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. Expert review of endocrinology & metabolism 2015; 10:297-304. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298772
  3. Schousboe JT, Kats AM, Langsetmo L et al. Central Obesity and Visceral Adipose Tissue Are Not Associated With Incident Atherosclerotic Cardiovascular Disease Events in Older Men. J Am Heart Assoc 2018; 7:e009172. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369326

Meta-analyses

  1. He Y, Li X, Gasevic D et al. Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Annals of internal medicine 2018; 169:543-553. http://www.ncbi.nlm.nih.gov/pubmed/?term=30304368
  2. Radaelli G, Sausen G, Cesa CC et al. Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis. Arquivos brasileiros de cardiologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30365601
  3. Nayak A, Hayen A, Zhu L et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open 2018; 8:e020584. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287603
  4. Peyser B, Perry EP, Singh K et al. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circulation. Genomic and precision medicine 2018; 11:e002228. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354330
  5. Koh KK. Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 138:1914-1915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354661
  6. Lorenzi M, Ambegaonkar B, Baxter CA et al. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical research in cardiology : official journal of the German Cardiac Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302558
  7. Balk EM, Adams GP, Langberg V et al. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Evidence report/technology assessment 2016:1-1252. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307737
  8. Salata K, Syed M, Hussain MA et al. Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2018; 7:e008657. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371297
  9. Vallejo-Vaz AJ, Ginsberg HN, Davidson MH et al. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc 2018; 7:e009221. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371190
  10. Penson PE, Mancini GBJ, Toth PP et al. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. Journal of cachexia, sarcopenia and muscle 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30311434
  11. Mirzaee S, Thein PM, Nogic J et al. The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. J Clin Lipidol 2018; 12:1133-1140.e1115. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318063
  12. Jang HJ, Kim HS, Kim JH, Lee J. The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials. Journal of clinical medicine 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287761
  13. Willeit P, Ridker PM, Nestel PJ et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30293769
  14. Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis 2018; 17:239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30326894
  15. Xiang Q, Zhang X, Ma L et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenetics and genomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30363031
  16. Choi GJ, Park HK, Kim DS et al. Effect of statins on experimental postoperative adhesion: a systematic review and meta-analysis. Scientific reports 2018; 8:14754. http://www.ncbi.nlm.nih.gov/pubmed/?term=30283040
  17. Poropat G, Archibugi L, Korpela T et al. Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies. United European gastroenterology journal 2018; 6:1206-1214. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288283

Metabolic Syndrome - Diabetes

  1. Pradhan AD, Paynter NP, Everett BM et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 2018; 206:80-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342298
  2. Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis 2018; 278:143-146. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278356
  3. Donzelli A, Schivalocchi A, Giudicatti G. Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 138:1912-1913. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354663
  4. Koh KK. Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 138:1914-1915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354661
  5. Verma S, Leiter LA, Mazer CD et al. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation 2018; 138:1605-1607. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354517
  6. Aminsharifi A, Howard LE, Amling CL et al. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clinical genitourinary cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30366879
  7. Mottl AK, Buse JB, Ismail-Beigi F et al. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361335
  8. Warraich HJ, Rana JS. Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. Current cardiology reports 2018; 20:125. http://www.ncbi.nlm.nih.gov/pubmed/?term=30311078
  9. Cavallari I, Delli Veneri A, Maddaloni E et al. Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current diabetes reports 2018; 18:138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30370486
  10. Grigoropoulou P, Tentolouris A, Eleftheriadou I et al. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research 2018:1479164118805320. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328360
  11. Donzelli A, Schivalocchi A, Giudicatti G, Battaggia A. Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275-1284. Diabetes Care 2018; 41:e143-e144. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348846
  12. Itoh H, Ueshima K, Komuro I. Response to Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275-1284. Diabetes Care 2018; 41:e145-e146. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348847
  13. Lan NSR, Fegan PG, Yeap BB et al. Dyslipidaemia in adults with type 1 diabetes - when to treat? Diabetes/metabolism research and reviews 2018:e3090. http://www.ncbi.nlm.nih.gov/pubmed/?term=30339719
  14. Nehme MA, Upadhyay A. Ezetimibe in the Treatment of Patients with Metabolic Diseases. European endocrinology 2013; 9:55-60. http://www.ncbi.nlm.nih.gov/pubmed/?term=30349611
  15. Nerild HH, Christensen MB, Knop FK, Bronden A. Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. Expert opinion on drug discovery 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336707
  16. Deseive S, Straub R, Kupke M et al. Impact of diabetes on coronary artery plaque volume by coronary CT angiography and subsequent adverse cardiac events. Journal of cardiovascular computed tomography 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30293793
  17. Carrillo-Ibarra S, Miranda-Diaz AG, Sifuentes-Franco S et al. Effect of statins on oxidative DNA damage in diabetic polyneuropathy. Journal of circulating biomarkers 2018; 7:1849454418804099. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302131
  18. Srivanichakorn W, Godsland IF, Washirasaksiri C et al. Cardiometabolic risk factors in Thai individuals with prediabetes treated in a high-risk, prevention clinic - unexpected relationship between HDL cholesterol and glycaemia in men. Journal of diabetes investigation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30387292
  19. Vanderholm T, Renner HM, Stolpe SF, Adams AJ. An Innovative Approach to Improving the Proposed CMS Star Rating "Statin Use in Persons with Diabetes". Journal of managed care & specialty pharmacy 2018; 24:1126-1129. http://www.ncbi.nlm.nih.gov/pubmed/?term=30362914
  20. Sorber R, Lehman A, Alshaikh HN et al. Metabolic syndrome is associated with increased cardiac morbidity after infrainguinal bypass surgery irrespective of the use of cardiovascular risk-modifying agents. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30292611
  21. Han KH. Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism. Korean Circ J 2018; 48:951-963. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334382
  22. Liu JM, Chen TH, Chuang HC et al. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30337635
  23. Parhofer KG. CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2018; 70:237-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307445
  24. Nimitphong H, Mahattanapreut A, Chailurkit LO et al. More evening preference is positively associated with systemic inflammation in prediabetes and type 2 diabetes patients. Scientific reports 2018; 8:15882. http://www.ncbi.nlm.nih.gov/pubmed/?term=30367094

New Treatments

  1. Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis 2018; 278:143-146. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278356
  2. Schol-Gelok S, Galema-Boers J, van Gelder T et al. No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 108:1412-1414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30372843
  3. Cavallari I, Delli Veneri A, Maddaloni E et al. Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current diabetes reports 2018; 18:138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30370486
  4. Tai MH, Shepherd J, Bailey H et al. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and United Kingdom. Current medical research and opinion 2018:1-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=30289004
  5. Athyros VG, Katsiki N, Dimakopoulou A et al. Drugs that mimic the effect of gene mutations for the prevention or the treatment of atherosclerotic disease: from PCSK9 inhibition to ANGPTL3 inactivation. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30306859
  6. Theocharidou E, Papademetriou M, Reklou A et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30317984
  7. Meyer D, Merkel M. [Hyperlipidemia: What role do PCSK9 inhibitors play?]. Deutsche medizinische Wochenschrift (1946) 2018; 143:1430-1434. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286489
  8. Pitts RN, Eckel RH. The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. European cardiology 2014; 9:65-70. http://www.ncbi.nlm.nih.gov/pubmed/?term=30310488
  9. Nicholls SJ, Puri R, Anderson T et al. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol 2018; 72:2012-2021. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336824
  10. Vallejo-Vaz AJ, Ginsberg HN, Davidson MH et al. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc 2018; 7:e009221. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371190
  11. Gaudet D, Langslet G, Gidding SS et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol 2018; 12:1199-1207. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318065
  12. Sarsam S, Berry A, Degheim G et al. Real-world use of PCSK9 inhibitors: A single-center experience. J Int Med Res 2018:300060518800595. http://www.ncbi.nlm.nih.gov/pubmed/?term=30280628
  13. Silbernagel G, Steiner LK, Hollstein T et al. The Interrelations between PCSK9-Metabolism and Cholesterol Synthesis and Absorption. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30323110
  14. Roder ME, Hildebrandt P, Storgaard H, Heitmann M. [Cholesterol-lowering treatment with PCSK9-inhibitors]. Ugeskrift for laeger 2018; 180. http://www.ncbi.nlm.nih.gov/pubmed/?term=30274588

Other

  1. Lin JH, Lin YF, Wang WJ et al. Plasma Aldosterone Concentration as a Determinant for Statin Use among Middle-Aged Hypertensive Patients for Atherosclerotic Cardiovascular Disease. Journal of clinical medicine 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355992
  2. Silbernagel G, Steiner LK, Hollstein T et al. The Interrelations between PCSK9-Metabolism and Cholesterol Synthesis and Absorption. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30323110
  3. Ye S, Leppin AL, Chan AY et al. An Informatics Approach to Implement Support for Shared Decision Making for Primary Prevention Statin Therapy. MDM policy & practice 2018; 3:2381468318777752. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288449
  4. Liang Z, Li W, Yang S et al. Tangier disease may cause early onset of atherosclerotic cerebral infarction: A case report. Medicine (Baltimore) 2018; 97:e12472. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278532
  5. Ridker PM. Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? N Engl J Med 2018; 379:1572-1574. http://www.ncbi.nlm.nih.gov/pubmed/?term=30332575

PAD and statins

  1. Khariton Y, Patel KK, Chan PS et al. Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30284297
  2. Tern PJW, Kujawiak I, Saha P et al. Site and Burden of Lower Limb Atherosclerosis Predicts Long-term Mortality in a Cohort of Patients With Peripheral Arterial Disease. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287208

Pleiotropic effects of statins

  1. Fahmy UA. Augmentation of Fluvastatin Cytotoxicity Against Prostate Carcinoma PC3 Cell Line Utilizing Alpha Lipoic-Ellagic Acid Nanostructured Lipid Carrier Formula. AAPS PharmSciTech 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30350252
  2. Unlu S, Nurkoc SG, Sezenoz B et al. Impact of statin use on high sensitive troponin T levels with moderate exercise. Acta Cardiol 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328783
  3. Rosas Saldarriaga D, Berrouet Mejia MC. Atorvastatin-Associated DRESS Syndrome. American journal of therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30272596
  4. He Y, Li X, Gasevic D et al. Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Annals of internal medicine 2018; 169:543-553. http://www.ncbi.nlm.nih.gov/pubmed/?term=30304368
  5. Sedki M, Khalil IA, El-Sherbiny IM. Hybrid nanocarrier system for guiding and augmenting simvastatin cytotoxic activity against prostate cancer. Artificial cells, nanomedicine, and biotechnology 2018:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30295086
  6. Schol-Gelok S, Galema-Boers J, van Gelder T et al. No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 108:1412-1414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30372843
  7. Nayak A, Hayen A, Zhu L et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open 2018; 8:e020584. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287603
  8. Langballe R, Cronin-Fenton D, Dehlendorff C et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. Br J Cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30353047
  9. Abdollahimajd F, Rajabi F, Shahidi-Dadras M et al. Pachyonychia congenita: A case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307612
  10. Ren C, Li S, Liu K et al. Enhanced oxidative stress response and neuroprotection of combined limb remote ischemic conditioning and atorvastatin after transient ischemic stroke in rats. Brain circulation 2017; 3:204-212. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276326
  11. Mondul AM, Joshu CE, Barber JR et al. Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study. Cancer prevention research (Philadelphia, Pa.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30327368
  12. Sreenivasan J, Khan MS, Li H et al. Statins and incidence of contrast-induced acute kidney injury following coronary angiography - Five year experience at a tertiary care center. Cardiovascular revascularization medicine : including molecular interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318173
  13. Marchetti DP, Steffens L, Jacques CE et al. Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-L-cysteine, Trolox, and Rosuvastatin. Cellular and molecular neurobiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302628
  14. Husain I, Khan S, Khan S et al. Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders. Clin Exp Pharmacol Physiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30290001
  15. Liu Z, Lai CH, Zhang X et al. Simvastatin ameliorates total liver ischemia/reperfusion injury via KLF2-mediated mechanism in rats. Clin Res Hepatol Gastroenterol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30274910
  16. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30314951
  17. Rea F, Calusi G, Franchi M et al. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation. Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361806
  18. Ghasemi A, Ghashghai Z, Akbari J et al. Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30291370
  19. Magdy YM, El-Kharashi OA, El-Waseef DAA et al. Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy. Experimental and molecular pathology 2018; 105:293-310. http://www.ncbi.nlm.nih.gov/pubmed/?term=30308196
  20. Boyle AK, Rinaldi SF, Rossi AG et al. Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018:fj201801104R. http://www.ncbi.nlm.nih.gov/pubmed/?term=30312114
  21. Braga Filho JAF, Abreu AG, Rios CEP et al. Prophylactic Treatment With Simvastatin Modulates the Immune Response and Increases Animal Survival Following Lethal Sepsis Infection. Frontiers in immunology 2018; 9:2137. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298072
  22. Goncalves RSG, Dantas AT, Pereira MC et al. Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis. Inflammation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288636
  23. Zhang H, Lu X, Liu Z, Du K. Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats. International journal of molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30320373
  24. Sinha P, Delucchi KL, Thompson BT et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive care medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30291376
  25. Deng LJ, Wu YL, He XH et al. Simvastatin delivery on PEEK for bioactivity and osteogenesis enhancements. Journal of biomaterials science. Polymer edition 2018:1-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=30307376
  26. Firouzi A, Kazem Moussavi A, Mohebbi A et al. Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention. Journal of cardiovascular and thoracic research 2018; 10:149-152. http://www.ncbi.nlm.nih.gov/pubmed/?term=30386535
  27. Cheng Y, Sun T, Yin C et al. Downregulation of PTEN by sodium orthovanadate protects the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30368869
  28. Yeh JJ, Lin CL, Hsu CY et al. Statin for Tuberculosis and Pneumonia in Patients with Asthma(-)Chronic Pulmonary Disease Overlap Syndrome: A Time-Dependent Population-Based Cohort Study. Journal of clinical medicine 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355982
  29. Zapata-Catzin GA, Bonilla-Hernandez M, Vargas-Coronado RF et al. Effect of the rigid segment content on the properties of segmented polyurethanes conjugated with atorvastatin as chain extender. Journal of materials science. Materials in medicine 2018; 29:161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357534
  30. Slomski A. Benefits May Persist After Antihypertensive and Statin Treatment. Jama 2018; 320:1631. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357296
  31. Du J, Zhu Y, Meng X et al. Atorvastatin attenuates paraquat poisoning-induced epithelial-mesenchymal transition via downregulating hypoxia-inducible factor-1 alpha. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336147
  32. El Sayed I, Helmy MW, El-Abhar HS. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30292831
  33. Basu S, Sussman JB, Hayward RA. Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit-Based Lipid and Blood Pressure Treatment. MDM policy & practice 2017; 2:2381468317725741. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288429
  34. Mollazadeh H, Atkin SL, Butler AE et al. The effect of statin therapy on endoplasmic reticulum stress. Pharmacol Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30312664
  35. Bogovic P, Lusa L, Stupica D et al. Impact of pre-existing treatment with statins on the course and outcome of tick-borne encephalitis. PLoS One 2018; 13:e0204773. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286159
  36. Liu JM, Chen TH, Chuang HC et al. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30337635
  37. Medeiros ADC, Azevedo IM, Lima ML et al. Effects of simvastatin on 5-fluorouracil-induced gastrointestinal mucositis in rats. Revista do Colegio Brasileiro de Cirurgioes 2018; 45:e1968. http://www.ncbi.nlm.nih.gov/pubmed/?term=30379218
  38. Pawar AM, LaPlante KL, Timbrook TT, Caffrey AR. Improved survival with continuation of statins in bacteremic patients. SAGE open medicine 2018; 6:2050312118801707. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364748
  39. Sanja M, Jozsef P, Sanja PG et al. Cytokines and statin therapy in chronic obstructive pulmonary disease patients. Scandinavian journal of clinical and laboratory investigation 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278779
  40. Choi GJ, Park HK, Kim DS et al. Effect of statins on experimental postoperative adhesion: a systematic review and meta-analysis. Scientific reports 2018; 8:14754. http://www.ncbi.nlm.nih.gov/pubmed/?term=30283040
  41. Nezic L, Skrbic R, Amidzic L et al. Simvastatin Protects Cardiomyocytes Against Endotoxin-induced Apoptosis and Up-regulates Survivin/NF-kappaB/p65 Expression. Scientific reports 2018; 8:14652. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279549
  42. Nunez-Garcia M, Gomez-Santos B, Saenz de Urturi D et al. Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice. Scientific reports 2018; 8:14626. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279550

Primary Prevention

  1. Vassy JL, Brunette CA, Majahalme N et al. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemporary clinical trials 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30367991
  2. Ye S, Leppin AL, Chan AY et al. An Informatics Approach to Implement Support for Shared Decision Making for Primary Prevention Statin Therapy. MDM policy & practice 2018; 3:2381468318777752. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288449

Registry data

  1. Hermans MP, Gevaert S, Descamps O et al. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II CHD). Acta clinica Belgica 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355016
  2. Crum J, Wilson J, Sabbagh M. Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimer's research & therapy 2018; 10:104. http://www.ncbi.nlm.nih.gov/pubmed/?term=30285877
  3. Beliard S, Boccara F, Cariou B et al. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Atherosclerosis 2018; 277:334-340. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270068
  4. Botha TC, Pilcher GJ, Wolmarans K et al. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis 2018; 277:502-507. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270091
  5. Cainzos-Achirica M, Enjuanes C, Greenland P et al. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2018; 278:217-225. http://www.ncbi.nlm.nih.gov/pubmed/?term=30312930
  6. Latkovskis G, Saripo V, Gilis D et al. Latvian registry of familial hypercholesterolemia: The first report of three-year results. Atherosclerosis 2018; 277:347-354. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270070
  7. Schmidt N, Dressel A, Grammer TB et al. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis 2018; 277:314-322. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270065
  8. Shek A, Alieva R, Kurbanov R et al. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle. Atherosclerosis 2018; 277:524-529. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270094
  9. Truong TH, Kim NT, Nguyen MNT et al. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis 2018; 277:392-398. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270076
  10. van Delden XM, Huijgen R, Wolmarans KH et al. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. Atherosclerosis 2018; 277:327-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270067
  11. Vrablik M, Raslova K, Vohnout B et al. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis 2018; 277:355-361. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270071
  12. Bergstrom H, Branvall E, Helde-Frankling M, Bjorkhem-Bergman L. Differences in discontinuation of statin treatment in women and men with advanced cancer disease. Biology of sex differences 2018; 9:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342545
  13. Chidwick K, Strongman H, Matthews A et al. Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink. BMC Cancer 2018; 18:1018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348123
  14. Langballe R, Cronin-Fenton D, Dehlendorff C et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. Br J Cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30353047
  15. Chen WC, Boursi B, Mamtani R, Yang YX. Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30333217
  16. Mondul AM, Joshu CE, Barber JR et al. Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study. Cancer prevention research (Philadelphia, Pa.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30327368
  17. Sreenivasan J, Khan MS, Li H et al. Statins and incidence of contrast-induced acute kidney injury following coronary angiography - Five year experience at a tertiary care center. Cardiovascular revascularization medicine : including molecular interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318173
  18. Oni-Orisan A, Hoffmann TJ, Ranatunga D et al. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circulation. Genomic and precision medicine 2018; 11:e002043. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354326
  19. Khariton Y, Patel KK, Chan PS et al. Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30284297
  20. Havers FP, Chung JR, Belongia EA et al. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371753
  21. Bodde MC, Hermans MPJ, Jukema JW et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical research in cardiology : official journal of the German Cardiac Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298424
  22. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30314951
  23. Moore N, Duret S, Grolleau A et al. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361989
  24. Rea F, Calusi G, Franchi M et al. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation. Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361806
  25. Tern PJW, Kujawiak I, Saha P et al. Site and Burden of Lower Limb Atherosclerosis Predicts Long-term Mortality in a Cohort of Patients With Peripheral Arterial Disease. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30287208
  26. Petrov IS, Postadzhiyan AS, Tokmakova MP et al. Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria. Folia medica 2018; 60:389-396. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355848
  27. Hussain MA, Saposnik G, Raju S et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc 2018; 7:e009745. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369318
  28. Kim J, Park KT, Jang MJ et al. High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention. J Am Heart Assoc 2018; 7:e009517. http://www.ncbi.nlm.nih.gov/pubmed/?term=30376751
  29. Lowenstern AM, Li S, Navar AM et al. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. J Am Heart Assoc 2018; 7:e009251. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371214
  30. Schousboe JT, Kats AM, Langsetmo L et al. Central Obesity and Visceral Adipose Tissue Are Not Associated With Incident Atherosclerotic Cardiovascular Disease Events in Older Men. J Am Heart Assoc 2018; 7:e009172. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369326
  31. Toth PP, Granowitz C, Hull M et al. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. J Am Heart Assoc 2018; 7:e008740. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371242
  32. Kajinami K, Ozaki A, Tajima Y et al. Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369517
  33. Banegas MP, Emerson MA, Adams AS et al. Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer. Journal of cancer survivorship : research and practice 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30338462
  34. Yeh JJ, Lin CL, Hsu CY et al. Statin for Tuberculosis and Pneumonia in Patients with Asthma(-)Chronic Pulmonary Disease Overlap Syndrome: A Time-Dependent Population-Based Cohort Study. Journal of clinical medicine 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30355982
  35. Yousufuddin M, Young N, Shultz J et al. Predictors of Recurrent Hospitalizations and the Importance of These Hospitalizations for Subsequent Mortality After Incident Transient Ischemic Attack. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30340936
  36. Wu CL, Kor CT, Chang CC et al. Association of Statin Use With Mortality After Dialysis-Requiring Acute Kidney Injury: A Population-Based Cohort Study. Mayo Clinic proceedings 2018; 93:1474-1483. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286832
  37. Guntekin U, Tosun V, Kilinc AY et al. ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals: A retrospective analysis of patients presenting with first acute coronary syndromes. Medicine (Baltimore) 2018; 97:e12225. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278492
  38. Yang Q, Yin RX, Cao XL et al. ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses. Nutrition & metabolism 2018; 15:70. http://www.ncbi.nlm.nih.gov/pubmed/?term=30323852
  39. Bogovic P, Lusa L, Stupica D et al. Impact of pre-existing treatment with statins on the course and outcome of tick-borne encephalitis. PLoS One 2018; 13:e0204773. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286159
  40. Woo Y, Shin JS, Shim CY et al. Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction. PLoS One 2018; 13:e0205006. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286170
  41. Liu JM, Chen TH, Chuang HC et al. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30337635
  42. Pawar AM, LaPlante KL, Timbrook TT, Caffrey AR. Improved survival with continuation of statins in bacteremic patients. SAGE open medicine 2018; 6:2050312118801707. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364748
  43. Yan MM, Wu SS, Ying YQ et al. Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE open medicine 2018; 6:2050312118798278. http://www.ncbi.nlm.nih.gov/pubmed/?term=30345053

Renal Disease

  1. Sreenivasan J, Khan MS, Li H et al. Statins and incidence of contrast-induced acute kidney injury following coronary angiography - Five year experience at a tertiary care center. Cardiovascular revascularization medicine : including molecular interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318173
  2. Tai MH, Shepherd J, Bailey H et al. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and United Kingdom. Current medical research and opinion 2018:1-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=30289004
  3. Alawami M, Wimalasena S, Ghashi R, Alnasrallah B. Acute Arterial Cardiovascular Events Risk in Patients with Primary Membranous Nephropathy. Internal medicine journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30346109
  4. Wu CL, Kor CT, Chang CC et al. Association of Statin Use With Mortality After Dialysis-Requiring Acute Kidney Injury: A Population-Based Cohort Study. Mayo Clinic proceedings 2018; 93:1474-1483. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286832

Safety and side effects

  1. Kuhlman AB, Morville T, Dohlmann TL et al. Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women; the LIFESTAT study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30273493
  2. Chen Y, Zhu R, Ma F et al. Assessment of OATP Transporter-Mediated Drug-Drug Interaction using Physiologically-Based Pharmacokinetic (PBPK) Modeling - A Case Example. Biopharmaceutics & drug disposition 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30335192
  3. Obreja E, Sequeira P, Girnita D. When Should a Patient with Statin-Induced Myopathy Be Re-challenged? A Case of Necrotizing Autoimmune Myopathy. Case Rep Rheumatol 2018; 2018:1215653. http://www.ncbi.nlm.nih.gov/pubmed/?term=30364043
  4. Peyser B, Perry EP, Singh K et al. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circulation. Genomic and precision medicine 2018; 11:e002228. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354330
  5. Tuteja S, Rader DJ. SLCO1B1 and Statin Therapy. Circulation. Genomic and precision medicine 2018; 11:e002320. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354338
  6. Peto R, Collins R. Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects. Circulation 2018; 138:1499-1501. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354509
  7. Wu X, Gong C, Weinstock J et al. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018:1076029618805863. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336686
  8. Havers FP, Chung JR, Belongia EA et al. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371753
  9. Parra-Virto A, Torres do Rego A, Demelo-Rodriguez P et al. Usefulness of compounds with monacolin K in a case of statins intolerance. Clin Investig Arterioscler 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30309697
  10. Mottl AK, Buse JB, Ismail-Beigi F et al. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361335
  11. Vassy JL, Brunette CA, Majahalme N et al. The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemporary clinical trials 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30367991
  12. Krysiak R, Szkrobka W, Okopien B. Atorvastatin potentiates the effect of selenomethionine on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis. Current medical research and opinion 2018:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354702
  13. Elsby R, Hare V, Neal H et al. Mechanistic in vitro studies indicate that the clinical drug-drug interaction between telithromycin and simvastatin acid is driven by time-dependent inhibition of CYP3A4 with minimal effect on OATP1B1. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348903
  14. Moore N, Duret S, Grolleau A et al. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361989
  15. Zuin M, Rigatelli G, L'Erario R et al. Herpes zoster infection and statins: which implications in clinical practice? European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298219
  16. Teschke R. Top ranking drugs out of 3312 drug induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. Expert Opin Drug Metab Toxicol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354694
  17. Chasioti D, Yao X, Zhang P et al. Mining directional drug interaction effects on myopathy using the FAERS database. IEEE journal of biomedical and health informatics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30296244
  18. Qu H, Guo M, Chai H et al. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2018; 7:e009835. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371340
  19. Penson PE, Mancini GBJ, Toth PP et al. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. Journal of cachexia, sarcopenia and muscle 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30311434
  20. Sawami K, Tanaka A, Nakamura T et al. Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia. Journal of cardiology cases 2018; 17:204-207. http://www.ncbi.nlm.nih.gov/pubmed/?term=30279893
  21. Carrillo-Ibarra S, Miranda-Diaz AG, Sifuentes-Franco S et al. Effect of statins on oxidative DNA damage in diabetic polyneuropathy. Journal of circulating biomarkers 2018; 7:1849454418804099. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302131
  22. Dohlmann TL, Morville T, Kuhlman AB et al. Statin treatment decreases mitochondrial respiration but muscle coenzyme Q10 levels are unaltered: The LIFESTAT study. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30299473
  23. Larsen S, Vigelso A, Dandanell S et al. Simvastatin-Induced Insulin Resistance May Be Linked to Decreased Lipid Uptake and Lipid Synthesis in Human Skeletal Muscle: the LIFESTAT Study. Journal of diabetes research 2018; 2018:9257874. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276217
  24. Desai NK, Mendelson MM, Baker A et al. Hepatotoxicity of Statins as determined by Serum Alanine Aminotransferase in a Pediatric Cohort with Dyslipidemia. Journal of pediatric gastroenterology and nutrition 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334928
  25. Barnett S, Ogungbenro K, Menochet K et al. Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared to rosuvastatin and coproporphyrin I. J Pharmacol Exp Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30314992
  26. Lee BC, Lin CL, Tsai HH, Kao CH. Statin and the Risk of Ischemic Stroke or Transient Ischemic Attack in Head and Neck Cancer Patients with Radiotherapy. J Stroke 2018; 20:413-414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30309238
  27. Yousufuddin M, Young N, Shultz J et al. Predictors of Recurrent Hospitalizations and the Importance of These Hospitalizations for Subsequent Mortality After Incident Transient Ischemic Attack. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30340936
  28. Moniri NH, Momary KM, McMahon T, Nayee E. Statin-Associated Achilles Tendon Rupture and Reproducible Bilateral Tendinopathy on Repeated Exposure. Mayo Clinic proceedings 2018; 93:1531-1532. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286837
  29. Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30375494
  30. Lim J, Rietveld A, De Bleecker JL et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurology(R) neuroimmunology & neuroinflammation 2019; 6:e513. http://www.ncbi.nlm.nih.gov/pubmed/?term=30345336
  31. McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30341597
  32. Xiang Q, Zhang X, Ma L et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenetics and genomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30363031
  33. Isackson PJ, Wang J, Zia M et al. RYR1 and CACNA1S genetic variants identified withf statin-associated muscle symptoms. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30325262
  34. Liu A, Wu Q, Guo J et al. Statins: adverse reactions, oxidative stress and metabolic interactions. Pharmacology & therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30321555
  35. Yan MM, Wu SS, Ying YQ et al. Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE open medicine 2018; 6:2050312118798278. http://www.ncbi.nlm.nih.gov/pubmed/?term=30345053
  36. Shah T, Virani SS. Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options. Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2018; 45:238-239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30374235
  37. Uchiyama H, Tsujimoto M, Kimura A et al. Effects of Uremic Serum Residue on OATP1B1- and OATP1B3-Mediated Pravastatin Uptake in OATP-Expressing HEK293 Cells and Human Hepatocytes. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318712
  38. Irwin JC, Fenning AS, Ryan KR, Vella RK. Validation of a clinically-relevant rodent model of statin-associated muscle symptoms for use in pharmacological studies. Toxicology and applied pharmacology 2018; 360:78-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=30268577
  39. Poropat G, Archibugi L, Korpela T et al. Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies. United European gastroenterology journal 2018; 6:1206-1214. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288283
  40. Takaguri A. [Elucidation of a New Mechanism of Onset of Insulin Resistance: Effects of Statins and Tumor Necrosis Factor-alpha on Insulin Signal Transduction]. Yakugaku Zasshi 2018; 138:1329-1334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30381640

Stroke and CNS

  1. Crum J, Wilson J, Sabbagh M. Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimer's research & therapy 2018; 10:104. http://www.ncbi.nlm.nih.gov/pubmed/?term=30285877
  2. Ren C, Li S, Liu K et al. Enhanced oxidative stress response and neuroprotection of combined limb remote ischemic conditioning and atorvastatin after transient ischemic stroke in rats. Brain circulation 2017; 3:204-212. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276326
  3. Husain I, Khan S, Khan S et al. Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders. Clin Exp Pharmacol Physiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30290001
  4. Chung PW, Yoon BW, Lee YB et al. Medication Adherence of Statin Users after Acute Ischemic Stroke. European neurology 2018; 80:106-114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30347393
  5. Kitagawa K, Hosomi N, Nagai Y et al. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318492
  6. Lee BC, Lin CL, Tsai HH, Kao CH. Statin and the Risk of Ischemic Stroke or Transient Ischemic Attack in Head and Neck Cancer Patients with Radiotherapy. J Stroke 2018; 20:413-414. http://www.ncbi.nlm.nih.gov/pubmed/?term=30309238
  7. Yousufuddin M, Young N, Shultz J et al. Predictors of Recurrent Hospitalizations and the Importance of These Hospitalizations for Subsequent Mortality After Incident Transient Ischemic Attack. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30340936
  8. Liang Z, Li W, Yang S et al. Tangier disease may cause early onset of atherosclerotic cerebral infarction: A case report. Medicine (Baltimore) 2018; 97:e12472. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278532
  9. Bogovic P, Lusa L, Stupica D et al. Impact of pre-existing treatment with statins on the course and outcome of tick-borne encephalitis. PLoS One 2018; 13:e0204773. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286159
  10. Liu JM, Chen TH, Chuang HC et al. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30337635
  11. Rahim F, Sayyah M. Effects of atorvastatin on treatment-resistant obsessive-compulsive disorder: A double-blind randomized trial. Psychiatria polska 2018; 52:719-729. http://www.ncbi.nlm.nih.gov/pubmed/?term=30368541

Triglycerides/HDL

  1. Di Bartolo BA, Psaltis PJ, Bursill CA, Nicholls SJ. Translating Evidence of HDL and Plaque Regression. Arterioscler Thromb Vasc Biol 2018; 38:1961-1968. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354261
  2. Bodde MC, Hermans MPJ, Jukema JW et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clinical research in cardiology : official journal of the German Cardiac Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30298424
  3. Chyzhyk V, Kozmic S, Brown AS et al. Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30352774
  4. Srivanichakorn W, Godsland IF, Washirasaksiri C et al. Cardiometabolic risk factors in Thai individuals with prediabetes treated in a high-risk, prevention clinic - unexpected relationship between HDL cholesterol and glycaemia in men. Journal of diabetes investigation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30387292
  5. Woo Y, Shin JS, Shim CY et al. Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction. PLoS One 2018; 13:e0205006. http://www.ncbi.nlm.nih.gov/pubmed/?term=30286170
  6. Han JS, Kim K, Jung Y et al. Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin. Scientific reports 2018; 8:14642. http://www.ncbi.nlm.nih.gov/pubmed/?term=302795

Trials

  1. Unlu S, Nurkoc SG, Sezenoz B et al. Impact of statin use on high sensitive troponin T levels with moderate exercise. Acta Cardiol 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328783
  2. Joseph P, Pais P, Dans AL et al. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. Am Heart J 2018; 206:72-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342297
  3. Pradhan AD, Paynter NP, Everett BM et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 2018; 206:80-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342298
  4. Kuhlman AB, Morville T, Dohlmann TL et al. Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women; the LIFESTAT study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30273493
  5. Ge Z, Baber U, Claessen BE et al. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30351514
  6. Koh KK. Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 138:1914-1915. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354661
  7. Verma S, Leiter LA, Mazer CD et al. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation 2018; 138:1605-1607. http://www.ncbi.nlm.nih.gov/pubmed/?term=30354517
  8. Mottl AK, Buse JB, Ismail-Beigi F et al. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361335
  9. Grigoropoulou P, Tentolouris A, Eleftheriadou I et al. Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research 2018:1479164118805320. http://www.ncbi.nlm.nih.gov/pubmed/?term=30328360
  10. Itoh H, Ueshima K, Komuro I. Response to Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275-1284. Diabetes Care 2018; 41:e145-e146. http://www.ncbi.nlm.nih.gov/pubmed/?term=30348847
  11. Lorenzatti A, Servato ML. Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). European cardiology 2018; 13:38-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=30310469
  12. de Knegt MC, Linde JJ, Fuchs A et al. Relationship between patient presentation and morphology of coronary atherosclerosis by quantitative multidetector computed tomography. European heart journal cardiovascular Imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30325406
  13. Ferrieres J, De Ferrari GM, Hermans MP et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol 2018:2047487318806359. http://www.ncbi.nlm.nih.gov/pubmed/?term=30335504
  14. Boulmpou A, Kartas A, Farmakis I et al. Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy compliance in patients with Acute Coronary Syndromes (IDEAL-LDL) Study: Rationale and design. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30352291
  15. Goncalves RSG, Dantas AT, Pereira MC et al. Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis. Inflammation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288636
  16. Sinha P, Delucchi KL, Thompson BT et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive care medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30291376
  17. Nicholls SJ, Puri R, Anderson T et al. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol 2018; 72:2012-2021. http://www.ncbi.nlm.nih.gov/pubmed/?term=30336824
  18. Hussain MA, Saposnik G, Raju S et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc 2018; 7:e009745. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369318
  19. Qu H, Guo M, Chai H et al. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2018; 7:e009835. http://www.ncbi.nlm.nih.gov/pubmed/?term=30371340
  20. Kitagawa K, Hosomi N, Nagai Y et al. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318492
  21. Carrillo-Ibarra S, Miranda-Diaz AG, Sifuentes-Franco S et al. Effect of statins on oxidative DNA damage in diabetic polyneuropathy. Journal of circulating biomarkers 2018; 7:1849454418804099. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302131
  22. Dohlmann TL, Morville T, Kuhlman AB et al. Statin treatment decreases mitochondrial respiration but muscle coenzyme Q10 levels are unaltered: The LIFESTAT study. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30299473
  23. Gaudet D, Langslet G, Gidding SS et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol 2018; 12:1199-1207. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318065
  24. Larsen S, Vigelso A, Dandanell S et al. Simvastatin-Induced Insulin Resistance May Be Linked to Decreased Lipid Uptake and Lipid Synthesis in Human Skeletal Muscle: the LIFESTAT Study. Journal of diabetes research 2018; 2018:9257874. http://www.ncbi.nlm.nih.gov/pubmed/?term=30276217
  25. J BS, Holleman RG, Youles B, Lowery JC. Quality Improvement and Personalization for Statins: the QUIPS Quality Improvement Randomized Trial of Veterans' Primary Care Statin Use. Journal of general internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30284172
  26. Silbernagel G, Steiner LK, Hollstein T et al. The Interrelations between PCSK9-Metabolism and Cholesterol Synthesis and Absorption. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30323110
  27. Desai NK, Mendelson MM, Baker A et al. Hepatotoxicity of Statins as determined by Serum Alanine Aminotransferase in a Pediatric Cohort with Dyslipidemia. Journal of pediatric gastroenterology and nutrition 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30334928
  28. Slomski A. Benefits May Persist After Antihypertensive and Statin Treatment. Jama 2018; 320:1631. http://www.ncbi.nlm.nih.gov/pubmed/?term=30357296
  29. Goh CC, Koh KH, Goh S et al. Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary care. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2018; 13:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30302178
  30. Basu S, Sussman JB, Hayward RA. Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit-Based Lipid and Blood Pressure Treatment. MDM policy & practice 2017; 2:2381468317725741. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288429
  31. Ye S, Leppin AL, Chan AY et al. An Informatics Approach to Implement Support for Shared Decision Making for Primary Prevention Statin Therapy. MDM policy & practice 2018; 3:2381468318777752. http://www.ncbi.nlm.nih.gov/pubmed/?term=30288449
  32. Liang Z, Li W, Yang S et al. Tangier disease may cause early onset of atherosclerotic cerebral infarction: A case report. Medicine (Baltimore) 2018; 97:e12472. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278532
  33. Sanja M, Jozsef P, Sanja PG et al. Cytokines and statin therapy in chronic obstructive pulmonary disease patients. Scandinavian journal of clinical and laboratory investigation 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30278779
  34. Choi GJ, Park HK, Kim DS et al. Effect of statins on experimental postoperative adhesion: a systematic review and meta-analysis. Scientific reports 2018; 8:14754. http://www.ncbi.nlm.nih.gov/pubmed/?term=30283040

Women and elderly

  1. Botha TC, Pilcher GJ, Wolmarans K et al. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis 2018; 277:502-507. http://www.ncbi.nlm.nih.gov/pubmed/?term=30270091
  2. Chimini JS, Possomato-Vieira JS, Silva M, Dias-Junior CA. Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30318719
  3. Bergstrom H, Branvall E, Helde-Frankling M, Bjorkhem-Bergman L. Differences in discontinuation of statin treatment in women and men with advanced cancer disease. Biology of sex differences 2018; 9:47. http://www.ncbi.nlm.nih.gov/pubmed/?term=30342545
  4. Rea F, Calusi G, Franchi M et al. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation. Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30361806
  5. Thompson W, Pottegard A, Nielsen JB et al. Correction to: How Common is Statin Use in the Oldest Old? Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30284119
  6. Boyle AK, Rinaldi SF, Rossi AG et al. Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018:fj201801104R. http://www.ncbi.nlm.nih.gov/pubmed/?term=30312114
  7. Singh S, Zieman S, Go AS et al. Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making. J Am Geriatr Soc 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30277567
  8. Schousboe JT, Kats AM, Langsetmo L et al. Central Obesity and Visceral Adipose Tissue Are Not Associated With Incident Atherosclerotic Cardiovascular Disease Events in Older Men. J Am Heart Assoc 2018; 7:e009172. http://www.ncbi.nlm.nih.gov/pubmed/?term=30369326
  9. Chyzhyk V, Kozmic S, Brown AS et al. Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30352774
  10. Lee OS, Zhang J, Jung SH et al. High-Intensity Statin Therapy Is "Too Much," Thus Not Indicated for Very Elderly Patients. Pulse (Basel, Switzerland) 2018; 6:19-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=30283750
  11. Shah T, Virani SS. Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options. Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2018; 45:238-239. http://www.ncbi.nlm.nih.gov/pubmed/?term=30374235

 
 

 
 
 

 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.